IP Verse

Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor - EP3142661

The patent EP3142661 was granted to Astrazeneca on Oct 6, 2021. The application was originally filed on May 14, 2015 under application number EP15726257A. The patent is currently recorded with a legal status of "Revoked".

EP3142661

ASTRAZENECA
Application Number
EP15726257A
Filing Date
May 14, 2015
Status
Revoked
Jun 14, 2024
Publication Date
Oct 6, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKJul 6, 2022TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS6515117
INTERNATIONAL-SEARCH-REPORTUS6774112
INTERNATIONAL-SEARCH-REPORTWO2009091082
INTERNATIONAL-SEARCH-REPORTWO2010092125
INTERNATIONAL-SEARCH-REPORTWO2014161918

Non-Patent Literature (NPL) Citations (3) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- ZAMBROWICZ BRIAN ET AL, "Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes", CLINICAL THERAPEUTICS, (201303), vol. 35, no. 3, doi:10.1016/j.clinthera.2013.01.010, pages 273 - 285.e7, XP002742650 [X] 1-8,10,11 * the whole document * [Y] 9,12 [I] 13-15
INTERNATIONAL-SEARCH-REPORT- JABBOUR SERGE A ET AL, "Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.", DIABETES CARE MAR 2014, (201403), vol. 37, no. 3, ISSN 1935-5548, pages 740 - 750, XP002742649 [X] 1-11,13-15 * the whole document * [Y] 12
INTERNATIONAL-SEARCH-REPORT- HANSEN LARS ET AL, "Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.", ENDOCRINE PRACTICE : OFFICIAL JOURNAL OF THE AMERICAN COLLEGE OF ENDOCRINOLOGY AND THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 1 NOV 2014, (20141101), vol. 20, no. 11, ISSN 1934-2403, pages 1187 - 1197, XP009185547 [XP] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents